Reporting from ASCO 2023 Annual Meeting, Alessandra Curioni-Fontecedro summarises the results from three important studies in advanced NSCLC. In the CHRYSALIS 2 study, predictive biomarkers were identified to target the specific population that achieved a remarkable 61% response rate with the combination of amivantamab and lazertinib. The CodeBreaK 200 study investigators conducted a biomarker subgroup analysis identifying KRAS G12C-mutated NSCLC subgroup with co-alterations where sotorasib did not outperform docetaxel. The third study addressed the issue of neoadjuvant osimertinib non-responders in an EGFR-mutated NSCLC population, highlighting the need for further exploration of heterogeneity and other genetic alterations.
Abstracts discussed:
- Abstract 9013: Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.
- Abstract 8508: Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer.
- Abstract 9008: Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).